Essential reading for healthcare providers including specialists, hospital physicians, general practitioners, nurses, pharmacists, clinical pharmacologists, formulary decision-makers, payers, and university and healthcare researchers. These journals offer: Large and global readership* Impact factors and discoverability Thorough peer review and efficient processes Accelerated publication options A publishing solution for every scientifically sound article
*Geographic distribution approximately 1/3 Americas, 1/3 EMEA, 1/3 Asia and ROW.
Publishing with AdisWe are committed to making the publication process as efficient as possible for our authors.
All Adis journals welcome pre-submission enquiries, accept original research and reviews, and welcome submissions of all types of studies (positive, negative or confirmatory).
We aim to find a journal for all research deemed sound by peer review. We will endeavor to cascade articles to an alternative, more suitable journal in the portfolio, if the manuscript cannot be accommodated in the original journal to which it was submitted.
Adis endorses the ICMJE / WAME / COPE Guidelines for Journal Editors, and encourages all manuscripts reporting sponsored research to comply with Good Publication Practice (GPP).
Adis also publishes books. To discuss any book ideas please contact our Editors at firstname.lastname@example.org, or visit our website, adis.com/books. We also develop custom book derivatives. Please visit our website, thinkingoutsidethebook.co.uk, for examples, or contact email@example.com for further information.
If you would like to find out more about publishing with Adis, visit adis.com/PublishingSolutions or contact:
Alessandro Gallo Springer Healthcare Italia Tel. +39 0254259721 firstname.lastname@example.org
Find out more
Adis JournalsPremier collection of drug-focused medical journalsPublishing definitive research and reviews on drugs, devices and other interventions
Journal Title Impact Factor
Advances in Therapy
2.272 Medline An international journal dedicated to rapid publication of studies in clinical medicine across all therapeutic areas and medical interventions related to drugs and devices. Extensive editorial board. Section leads include: R. Rizzoli (Rheum), R. McIntyre (Psych), I. Menown (Cardio), C. Twelves (Onc), A. Veves (Diabetes), K. Beeh (Resp)
American Journal of Cardiovascular Drugs
2.422 Medline Open ChoiceAdis Drug Evaluations
Promotes rational therapy and effective patient management in cardiovascular medicine. Publishes reviews and original research articles covering all aspects of the management of cardiovascular disorders, particularly the place in therapy of newer and established drugs, devices, and other interventions. Editor-in-Chief: Amitabh Prakash
American Journal of Clinical Dermatology
2.725 Medline Open ChoiceAdis Drug EvaluationsTop 50 ISI
Promotes rational therapy and effective patient management in dermatology. Publishes reviews and original research articles covering all aspects of the management of dermatological conditions, particularly the place in therapy of newer and established agents and procedures. Editor-in-Chief: Kathy Fraser
Applied Health Economics & Health Policy
1.710* Medline Open Choice Publishes original research and review articles on the economic implications of healthcare interventions, economic consequences of policy initiatives, and analyses of pricing and reimbursement systems. Of high interest to healthcare payers and providers, health economists and outcomes researchers, and healthcare policy and decision-makers. Editor-in-Chief: Tim Wrightson
BioDrugs 2.989 Medline Open ChoiceAdis Drug Evaluations
Publishes original research and reviews of the latest developments in the clinical application of biotechnology for the treatment of human disease, including aspects of target selection, drug development and delivery, and clinical use of biologics and molecularly targeted therapeutics. Editor-in-Chief: Joanne Beachman
Cardiology and Therapy
N/A PubMed Open accessRapid+ Service
Publishes papers in all areas of cardiology, including interventional cardiology, acute coronary syndrome, arrhythmia, stroke/atrial fibrillation and thrombosis, diabetes, electrophysiology, heart failure, hypertension, imaging, intervention/surgery, lipid metabolism, and prevention and management of cardiovascular disease, and device-related therapies. Editors-in-Chief: Robert Giugliano (USA), Uwe Zeymer (Europe), Ian Menown (Interventional)
Clinical Drug Investigation
1.557 Medline Open ChoiceAdis Drug Evaluations
Publishes original research covering all phases of clinical drug development and therapeutic use of drugs and drug devices, as well as pharmacoeconomic and outcomes research, across all therapeutic areas. Editor-in-Chief: Jasbir Singh
5.053 Medline Open ChoiceTop 50 ISI
Promotes continuing development of clinical pharmacokinetics and pharmacodynamics to optimize drug therapy, and to further postgraduate education in clinical pharmacology and therapeutics. Editor-in-Chief: Amitabh Prakash
CNS Drugs 5.113 Medline Open ChoiceAdis Drug EvaluationsTop 50 ISI
Promotes rational pharmacotherapy and effective patient management within the disciplines of clinical psychiatry and neurology. Publishes reviews and original research articles covering important issues in the drug treatment of psychiatric and neurological disorders. Editors-in-Chief: Kate Palmer, Sue Pochon
Dermatology and Therapy
Medline due 2016
Open accessRapid+ Service
Covers all clinical aspects of dermatology including skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of esthetic dermatology, including skin maintenance, dermatological surgery, and lasers and other device-related therapies. Editors-in-Chief: Alan Menter (USA), Richard Warren (Europe)
Diabetes Therapy 2.915* PubMed
Medline due 2016
Open accessRapid+ Service
Focuses on cutting-edge research in the prevention, treatment, management, and education of diabetes and related disorders, including obesity and metabolic syndromes, as well as device-related therapies. Editors-in-Chief: Fernando Ovalle (USA), Marc Evans (Europe)
Open ChoiceRapid+ Service
*Article processing charge applies for Open Choice/Open Access; additional charges apply for Rapid+ Service and VIP Service
Open Choice*Our Open Choice program allows authors to publish open access in the Adis subscription-based journals. Open Choice articles are freely available online immediately upon publication, clearly labelled on SpringerLink using an open access button, with authors retaining non-commercial copyright. Open Choice articles are automatically exported to PubMed Central/Europe PubMed Central.
Open Access*Fully open access journal with unrestricted online access. Authors retain non-commercial copyright to their work, and all articles comply with open access mandates, including re-use and immediate deposit of final article version in any repository.
Key for contents of the tables featured on pages 2, 3 and 4
Journal Title Impact Factor
Drug Safety 2.824 Medline Open ChoiceTop 50 ISI
Advances the rational use of pharmacotherapy by publishing reviews and original research articles offering guidance for safe and effective drug utilization and prescribing. Of high interest to healthcare professionals, regulators, and pharma industry personnel with an interest in drug safety, pharmacovigilance and pharmacoepidemiology. Editor-in-Chief: Nitin Joshi
Drug Safety Case Reports
N/A PubMed due 2015**
Open access Specializes in the publication of case reports and case series relating to suspected adverse drug reactions, as well as reports of any unintended or adverse effects following administration of a medicinal product (or products). The journal welcomes reports of cases involving near misses (for example, medication errors detected before harm is done), and cases involving the lack of efficacy of a therapeutic product. Editors: N. Joshi; S. McMillan
Drugs 4.343 Medline Open ChoiceAdis Drug EvaluationsTop 50 ISI
Promotes optimum pharmacotherapy by publishing reviews covering the most important aspects of clinical pharmacology and therapeutics. Drugs also includes Adis Drug Evaluations, current reviews on drugs receiving a first global approval, and original research articles reporting pivotal late-phase clinical trials. Editor-in-Chief: Dene Peters
Drugs & Aging 2.838 Medline Open ChoiceAdis Drug EvaluationsTop 50 ISI
Promotes optimum drug therapy in older adults through reviews and original research articles covering the most important aspects of clinical pharmacology and patient management in this patient group. Physiological changes during aging that have implications for drug therapy also fall within the scope of the journal. Editor-in-Chief: David Williamson
Drugs & Therapy Perspectives
N/A N/A Open Choice Concise, authoritative guidance on the choice and clinical use of drugs for all healthcare professionals. The journal includes differential features tables, step-by-step patient care guidelines, overviews of drugs and their place in therapy, questions and answers on the clinical use of drugs, current thinking on disease management, clinically useful pharmacodynamics and pharmacoeconomics, hot topics in adverse